Targeting RAS Mutant Colorectal Cancer with Dual Inhibition of MEK and CDK4/6.

Alexey V SorokinPreeti Kanikarla MarieLea BitnerMuddassir SyedMelanie WoodsGaniraju C ManyamLawrence N KwongBenny Johnson Van Karlyle Morris Philip Jones David G Menter Michael S Lee Edmund S Kopetz

Published in: Cancer research (2022)

This co-clinical trial of combined MEK-CDK4/6 inhibition in RAS mutant colorectal cancer demonstrates therapeutic efficacy in patient-derived xenografts and safety in patients, identifies biomarkers of response, and uncovers targetable mechanisms of resistance.

Keyphrases

wild type
clinical trial
end stage renal disease
cell cycle
newly diagnosed
prognostic factors
patient reported outcomes
randomized controlled trial
gene expression
open label
drug delivery
signaling pathway
placebo controlled